Our finding is consistent with clinical reports that PTEN mutations are more frequently found in female patients with cancers such as breast and endometrial cancers (11% within the general population), while males with PTEN mutations have a lower (<1% within the general population) chance of developing cancers than females (Blumenthal and Dennis, 2008). This evidence concerns the gene PTEN and cancer.